Water, Ascorbyl Palmitate, Urea, Butylene Glycol Dicaprylate/Dicaprate, Dimethicone, Acetyl Tyrosine, Dimethyl MEA, Fragrance, Zinc Sulfate, Sodium Hydroxide, Tocopheryl, Acetate, Panthenol, Sodium Hyaluronate, Ergothioneine, Pyridoxine HCl, Sodium Metabisulfite, Sodium Sulfite, Xanthan Gum, Disodium EDTA, Citric Acid, Famesol, Linalool, Amyl Cinnamal, Benzyl Salicylate, Cinnamal, Limonene, Eugenol, Geraniol, Hydroxycitronellal, Butylphenyl Methylpropional, Caprylyl Glycol, Ethylhexylglycerin, Hexylene Glycol, Phenoxyethanol
All KLD peptides are produced in the United States and tested by certified third-party laboratories
Releasing Q2 earnings on Monday, Hims & Hers Co-Founder and CEO Andrew Dudem said users of its personalized GLP-1 treatment plans had lost an average 10.3% of their body weight over six months, and that only 25% of them had discontinued treatment, particularly encouraging when considering discontinuation rates in certain publicly available studies reached approximately 80% percent by six months. Saying that personalized treatments allow patients to receive clear treatment instructions and educational content while also accessing tools such as water intake trackers and calorie counters, Dudem complained of pushback from traditional incumbents. During its own earnings call on Wednesday, Novo Nordisk doubled down against GLP-1 compounders that it says are still around despite the end of an FDA-granted grace period in May
GLP-1 medicines are prescription medicines used to treat diabetes and, in some instances, support weight management
Our focus on providing safe, provider-supervised services has allowed us to become a reliable resource for those exploring wellness options